Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Elisabetta Fratto

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|February 7, 2012
Perspectives in the elderly patient: benefits and limits of bisphosphonates and denosumabDaniele Santini, Maria Elisabetta Fratto, Matti Aapro
Critical Reviews in Oncology/Hematology|August 12, 2008
Are bisphosphonates the suitable anticancer drugs for the elderly?Daniele Santini, Maria Elisabetta Fratto, Sara Galluzzo, et al.
Expert Opinion on Biological Therapy|January 16, 2008
Hormono-biological therapy in metastatic breast cancer: preclinical evidence, clinical studies and future directionsGiuseppe Tonini, Gaia Schiavon, Maria Elisabetta Fratto, et al.
Expert Opinion on Biological Therapy|January 17, 2007
Zoledronic acid in the management of metastatic bone diseaseDaniele Santini, Maria Elisabetta Fratto, Bruno Vincenzi, et al.
Future Oncology (London, England)|December 17, 2009
Targeted therapy in biliary tract cancer: 2009 updateGiuseppe Tonini, Vladimir Virzì, Maria Elisabetta Fratto, et al.
Expert Review of Anticancer Therapy|June 29, 2011
Predictive factors of response to treatment in patients with metastatic renal cell carcinoma: new evidenceGiuseppe Tonini, Maria Elisabetta Fratto, Marco Imperatori, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 28, 2021
Drug Prices and Value of Oncology Drugs in ItalyPierluigi Russo, Andrea Marcellusi, Matteo Zanuzzi, et al.
Current Cancer Drug Targets|January 22, 2010
Can we consider zoledronic acid a new antitumor agent? Recent evidence in clinical settingDaniele Santini, Vladimir Virzi, Maria Elisabetta Fratto, et al.
Frontiers in Bioscience (Scholar Edition)|January 4, 2011
Targeting EGFR in bilio-pancreatic and liver carcinomaMaria Elisabetta Fratto, Daniele Santini, Bruno Vincenzi, et al.
Cancer Immunology, Immunotherapy : CII|May 7, 2008
In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patientsDaniele Santini, Federico Martini, Maria Elisabetta Fratto, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|February 7, 2012
Perspectives in the elderly patient: benefits and limits of bisphosphonates and denosumabDaniele Santini, Maria Elisabetta Fratto, Matti Aapro
Critical Reviews in Oncology/Hematology|August 12, 2008
Are bisphosphonates the suitable anticancer drugs for the elderly?Daniele Santini, Maria Elisabetta Fratto, Sara Galluzzo, et al.
Expert Opinion on Biological Therapy|January 16, 2008
Hormono-biological therapy in metastatic breast cancer: preclinical evidence, clinical studies and future directionsGiuseppe Tonini, Gaia Schiavon, Maria Elisabetta Fratto, et al.
Expert Opinion on Biological Therapy|January 17, 2007
Zoledronic acid in the management of metastatic bone diseaseDaniele Santini, Maria Elisabetta Fratto, Bruno Vincenzi, et al.
Future Oncology (London, England)|December 17, 2009
Targeted therapy in biliary tract cancer: 2009 updateGiuseppe Tonini, Vladimir Virzì, Maria Elisabetta Fratto, et al.
Expert Review of Anticancer Therapy|June 29, 2011
Predictive factors of response to treatment in patients with metastatic renal cell carcinoma: new evidenceGiuseppe Tonini, Maria Elisabetta Fratto, Marco Imperatori, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 28, 2021
Drug Prices and Value of Oncology Drugs in ItalyPierluigi Russo, Andrea Marcellusi, Matteo Zanuzzi, et al.
Current Cancer Drug Targets|January 22, 2010
Can we consider zoledronic acid a new antitumor agent? Recent evidence in clinical settingDaniele Santini, Vladimir Virzi, Maria Elisabetta Fratto, et al.
Frontiers in Bioscience (Scholar Edition)|January 4, 2011
Targeting EGFR in bilio-pancreatic and liver carcinomaMaria Elisabetta Fratto, Daniele Santini, Bruno Vincenzi, et al.
Cancer Immunology, Immunotherapy : CII|May 7, 2008
In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patientsDaniele Santini, Federico Martini, Maria Elisabetta Fratto, et al.
Pageof 2